Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

One third of patients who stop treatment for schizophrenia early do so due to poor response

23.12.2005


A third of patients treated for schizophrenia who stop taking their medication early do so because they do not feel any significant improvement or because their symptoms are worsening. A study published today in the open access journal BMC Medicine reveals that patients with schizophrenia are three times more likely to stop treatment because of poor response or worsening symptoms, than because of adverse non-psychiatric side effects.



Hong Liu-Seifert and colleagues from Eli Lilly and Company in Indianapolis, USA, analysed the reasons for stopping treatment of patients who took part in four previous Eli Lilly studies. The studies included a total of 1627 patients and compared the effects of taking olanzapine, risperidone, quetiapine or ziprasidone in patients diagnosed with schizophrenia or related disorders.

Liu-Seifert et al.’s analysis shows that 53% (866/1627) of patients stopped treatment early. Of the 866 patients who stopped treatment, 36% (315/866) did so because the treatment was felt not to be effective or because their symptoms worsened. Only 12% of patients who stopped treatment early did so because of adverse events such as dizziness, fatigue, vomiting or weight gain.


Of the 315 patients who stopped because of poor response to treatment, 80% stopped because they themselves believed it wasn’t effective. Only 20% of the patients studied stopped taking medication based on a doctor’s decision that the treatment wasn’t effective.

"Discontinuation due to patient perception of poor response appeared to occur particularly early in the course of treatment," the authors write. Liu-Seifert et al. found that patients who experienced an early response to medication were 80% more likely to complete treatment.

The authors’ findings suggest that early and effective symptom control, and discussing expectations of treatment, may help to ensure that people suffering from schizophrenia continue to take their medication.

Juliette Savin | alfa
Further information:
http://www.biomedcentral.com

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>